For the quarter ending 2026-03-31, ETON made $24,266,000 in revenue. $1,554,000 in net income. Net profit margin of 6.40%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total net revenues | 24,266,000 | 21,281,000 | 22,459,000 | 18,928,000 |
| License | 0 | 0 | 0 | 0 |
| Product Sales And Royalties | 9,531,000 | 8,181,000 | 14,604,000 | 7,004,000 |
| Total cost of sales | 9,531,000 | 8,181,000 | 14,604,000 | 7,004,000 |
| Gross profit | 14,735,000 | 13,100,000 | 7,855,000 | 11,924,000 |
| Research and development | 1,875,000 | 1,780,000 | 1,112,000 | 3,712,000 |
| General and administrative | 10,446,000 | 8,856,000 | 8,106,000 | 9,687,000 |
| Total operating expenses | 12,321,000 | 10,636,000 | 9,218,000 | 13,399,000 |
| Income (gain) from operations | 2,414,000 | 2,464,000 | -1,363,000 | -1,475,000 |
| Interest and other (expense) income, net | - | -1,050,000 | - | - |
| Interest and other expense, net | -840,000 | - | -592,000 | -1,044,000 |
| Income (gain) before income tax expense | 1,574,000 | 1,414,000 | -1,955,000 | -2,519,000 |
| Income tax expense | 20,000 | -69,000 | -28,000 | 66,000 |
| Net income (gain) | 1,554,000 | 1,483,000 | -1,927,000 | -2,585,000 |
| Basic EPS | 0.06 | 0.055 | -0.07 | -0.1 |
| Diluted EPS | 0.05 | - | -0.07 | - |
| Basic Average Shares | 27,285,000 | 26,960,000 | 26,893,000 | 26,893,000 |
| Diluted Average Shares | 31,547,000 | - | 26,893,000 | - |
Eton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals, Inc. (ETON)